Standards For Early Alzheimer’s Drugs Adapted, Not Loosened, FDA’s Katz Says
This article was originally published in The Pink Sheet Daily
A draft guidance for development of drugs to treat early Alzheimer’s disease does not loosen agency standards, FDA’s neurology products chief asserts. Rather, it is an attempt to establish criteria tailored to the population.
You may also be interested in...
In another sign of uncertainty for Alzheimer’s disease drug development, Lilly shakes things up with announcement of design changes for Phase III trial for solanezumab.
Biotech shifts development plans after Phase II study shows surprising, but promising, results – albeit in the wrong arm of the study.
Eisai should get the first feedback from an adaptive Phase II trial of BAN2401 in Alzheimer’s patients with mild cognitive impairment in six or seven months, offering the first opportunity to adjust parameters testing dose response and the antibody’s disease-modifying potential or to stop the trial early for futility.